Cytosorbents (NASDAQ:CTSO) Issues Earnings Results

Cytosorbents (NASDAQ:CTSO) released its quarterly earnings data on Thursday. The medical research company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.03), Zacks reports. The company had revenue of $9.63 million for the quarter, compared to analyst estimates of $9.38 million. Cytosorbents had a negative return on equity of 309.53% and a negative net margin of 48.94%.

Here are the key takeaways from Cytosorbents’ conference call:

• Profitability and cash-burn trends improved: Second-quarter gross margin rose to 73%, adjusted EBITDA loss improved 38% year over year, and operating cash burn fell to approximately $200,000 excluding restructuring payments. Management reiterated its expectation of reaching operating cash-flow breakeven in the second half of 2026.
• Revenue remained essentially flat at $9.6 million: Distributor and strategic-partner revenue increased 16% year over year and direct sales outside Germany rose 9%, offset by continued weakness in Germany and Middle East disruptions. The company plans to add three to five German sales representatives through early 2027.
• DrugSorb-ATR still faces regulatory uncertainty: The FDA previously denied the company’s de novo application because the pivotal STAR-T trial missed its primary endpoint, although management said a new clinical trial is not required. Cytosorbents plans to submit additional mechanistic data and real-world evidence, with separate FDA discussions planned for the ticagrelor and DOAC indications.
• Management highlighted favorable DrugSorb-ATR secondary analyses: In the CABG per-protocol population, the severe-bleeding endpoint achieved a statistically significant win ratio of 1.59, while a composite of severe bleeding or more than one liter of chest-tube blood loss showed a reported 58% relative risk reduction. These analyses may support a renewed FDA submission, though they do not eliminate the prior primary-endpoint miss.
• HemoDefend-BGA represents longer-term strategic optionality rather than current revenue: The universal-plasma technology has completed development and received constructive FDA feedback on a potential clinical pathway, but Cytosorbents does not plan to fund clinical trials from its current resources. Progress depends on government funding, partnerships, licensing, or another strategic transaction.

Cytosorbents Trading Down 9.7%

Cytosorbents stock traded down $0.04 during mid-day trading on Friday, hitting $0.36. The company’s stock had a trading volume of 96,364 shares, compared to its average volume of 61,883. The stock’s fifty day moving average is $0.40 and its two-hundred day moving average is $0.55. The company has a current ratio of 1.09, a quick ratio of 0.81 and a debt-to-equity ratio of 4.70. The firm has a market capitalization of $22.62 million, a PE ratio of -1.24 and a beta of 1.39. Cytosorbents has a 1 year low of $0.35 and a 1 year high of $1.22.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Cytosorbents in a report on Monday, July 6th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Cytosorbents presently has an average rating of “Hold” and an average price target of $5.38.

Insider Buying and Selling

In other Cytosorbents news, CEO Phillip P. Chan purchased 251,136 shares of the firm’s stock in a transaction dated Friday, June 12th. The shares were acquired at an average price of $0.40 per share, with a total value of $100,454.40. Following the purchase, the chief executive officer directly owned 1,734,099 shares in the company, valued at approximately $693,639.60. This trade represents a 16.93% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 7.80% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cytosorbents

Institutional investors have recently made changes to their positions in the stock. Avenir Corp boosted its position in shares of Cytosorbents by 2.9% during the 4th quarter. Avenir Corp now owns 5,230,099 shares of the medical research company’s stock worth $3,343,000 after purchasing an additional 147,261 shares during the period. CIBC Bancorp USA Inc. purchased a new position in shares of Cytosorbents during the third quarter worth $161,000. Vanguard Group Inc. grew its stake in shares of Cytosorbents by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,204,294 shares of the medical research company’s stock valued at $2,059,000 after buying an additional 79,535 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of Cytosorbents by 149.2% in the first quarter. Goldman Sachs Group Inc. now owns 62,662 shares of the medical research company’s stock valued at $63,000 after buying an additional 37,519 shares in the last quarter. Finally, Citadel Advisors LLC raised its holdings in shares of Cytosorbents by 127.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,690 shares of the medical research company’s stock valued at $61,000 after buying an additional 36,790 shares during the period. 32.87% of the stock is currently owned by institutional investors and hedge funds.

Cytosorbents Company Profile

Cytosorbents Corporation, founded in 2011 and headquartered in Princeton, New Jersey, is a medical device company focused on critical care and extracorporeal blood purification. The company’s flagship product, CytoSorb, is a hemoadsorption cartridge designed to remove excessive inflammatory mediators such as cytokines, bilirubin and myoglobin from a patient’s blood. By targeting the molecular drivers of hyperinflammation, CytoSorb is intended to stabilize patients undergoing septic shock, cardiac surgery, trauma and organ failure.

CytoSorb has secured regulatory clearance in Europe (CE mark) and is available in more than 65 countries, with a growing presence in Asia, the Middle East and Latin America.